By Review Flags Conflicting Product Details
A consumer review published September 17, 2026 on Newswire.com examined Radiant CBD Gummies, a hemp-derived product marketed as a wellness gummy. The review reported that the current product page and an earlier documented source do not match.
According to the review, the sources “don’t agree on spectrum type, dose, or count.” The publication stated it could not confirm whether the product was reformulated, whether it is a different SKU, or whether one source is simply wrong.
The review noted that full spectrum and isolate are not interchangeable, a difference affecting both the experience and drug-testing risk for some buyers. It recommended emailing Radiant for the current supplement facts panel and a Certificate of Analysis.
An earlier ACCESS Newswire report from April 30, 2026 documented the isolate figures. That report stated each container holds thirty servings and delivers 33.8 milligrams of CBD per gummy per the supplement facts panel.
The product is distributed by Radiant Boost out of Sunrise, Florida, and sold direct-to-consumer through buyradiantcbd.com.
Pricing And Guarantee Questions
The September review examined current pricing, free shipping, and guarantee coverage. It cautioned that “normal price” and savings figures are the brand’s own displayed reference points, not an independently audited price history.
The review noted the landing page shows a limited-stock message and countdown graphic. It described that styling as standard promotion rather than a confirmed inventory count.
The ACCESS Newswire report stated pricing starts at $39.74 per bottle on the largest multi-bottle bundle. Free shipping is included on every bundle tier.
The September review reported that guarantee terms include both confirmed and unconfirmed elements. It advised buyers to verify refund coverage before ordering.
Both publications disclosed that commissions are earned through purchase links.
Regulatory Context And Buyer Guidance
The September review emphasized that hemp being excluded from the federal Controlled Substances Act is not the same as CBD being federally legal in every sense. The FDA separately regulates CBD in foods and supplements.
The review noted a federal hemp-law change on September 2, 2026 relevant to the product category. It described the product as the brand positions it, a wellness gummy, rather than an FDA-approved treatment.
The review advised certain groups to consult a professional first, including pregnant or breastfeeding readers, citing FDA advice against CBD use in both cases.
It also urged anyone on prescription or OTC medications to check with a pharmacist, since CBD can interact with certain drugs.
Anyone subject to drug testing in any context was advised to hold off or seek guidance before purchasing.
